aff

Antibody affinity defines binding strength. Biointron explains its role in potency, therapeutic success, and the development of optimized antibodies.

Engineering CDR loops boosts binding strength. Biointron outlines strategies to optimize CDRs for developing potent therapeutic antibodies.

Somatic hypermutation drives high-affinity antibodies. Biointron explains its role in B cell evolution and therapeutic antibody optimization.

Affinity maturation enhances antibody binding strength. Biointron explains in vivo and in vitro approaches that optimize therapeutic potential and performance with AI and NGS technologies.

Antibody mimetics are engineered proteins that replicate antibody binding. Biointron explores their unique properties and potential advantages in therapy and research.

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Master affinity maturation from in vivo somatic hypermutation to in vitro selection. Biointron’s FCMES-AM™ platform accelerates optimization for higher binding and specificity.

Learn how antibody optimization techniques like humanization, deimmunization, affinity maturation & Fc engineering improve therapeutic antibodies.